Matches in Wikidata for { <http://www.wikidata.org/entity/Q57705930> ?p ?o ?g. }
- Q57705930 description "article scientifique publié en 2018" @default.
- Q57705930 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q57705930 description "im Juni 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57705930 description "scientific article published on 15 June 2018" @default.
- Q57705930 description "wetenschappelijk artikel" @default.
- Q57705930 description "наукова стаття, опублікована у вересні 2018" @default.
- Q57705930 description "գիտական հոդված հրատարակված 2018 թվականի հունիսի 15-ին" @default.
- Q57705930 name "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 name "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 type Item @default.
- Q57705930 label "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 label "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 prefLabel "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 prefLabel "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 P1433 Q57705930-E3D3F1A0-24C8-40F0-8DC6-7489AE22A358 @default.
- Q57705930 P1476 Q57705930-E2FBE897-C971-4D68-ABCA-6FA95CE33AD1 @default.
- Q57705930 P2093 Q57705930-1742B9AB-7518-448A-86FB-B572E05DF673 @default.
- Q57705930 P2093 Q57705930-4F498D76-8D9C-499F-8523-B077D1104A8D @default.
- Q57705930 P2093 Q57705930-7C9BA4C4-2972-4EB7-92FC-BFFAB4C63BD0 @default.
- Q57705930 P2093 Q57705930-93030EC4-7018-41F0-8539-6D358B82B542 @default.
- Q57705930 P2860 Q57705930-00834778-D451-4C0B-A8D3-7ADEC8BF1848 @default.
- Q57705930 P2860 Q57705930-0276A96A-0BA1-4679-9B17-2097DE8A7A9E @default.
- Q57705930 P2860 Q57705930-0C2C1A39-CC7B-4D8B-869D-49CF60C0009A @default.
- Q57705930 P2860 Q57705930-0E4D5B5A-66F3-46FD-A4DA-1B7239789438 @default.
- Q57705930 P2860 Q57705930-31C2F8A0-F7F2-4CC4-96A6-6C700B485583 @default.
- Q57705930 P2860 Q57705930-326C41B3-FE49-405C-947A-2259EE41923C @default.
- Q57705930 P2860 Q57705930-3360C23C-79FA-4420-A340-A74E50631EC2 @default.
- Q57705930 P2860 Q57705930-347961A7-C1B2-436A-8EDD-6927F76011AA @default.
- Q57705930 P2860 Q57705930-4E7CD057-B14B-410F-B1FE-36F65BAC6300 @default.
- Q57705930 P2860 Q57705930-502ABC63-6026-48A8-99EF-1BDB878157DA @default.
- Q57705930 P2860 Q57705930-57857D4B-E95C-4DFD-A74B-1FE901521606 @default.
- Q57705930 P2860 Q57705930-7777C545-BB24-4382-8AAE-62AA006E9EED @default.
- Q57705930 P2860 Q57705930-8AD5EBC0-ABB1-4080-918B-E8851A74E603 @default.
- Q57705930 P2860 Q57705930-9CF19146-8B2F-4533-AB7F-C15C313AC890 @default.
- Q57705930 P2860 Q57705930-9D173D16-B1DB-4E6C-913D-AAB55EBF7FFC @default.
- Q57705930 P2860 Q57705930-BE796707-3DC8-4477-A62B-58CDF313AA6D @default.
- Q57705930 P2860 Q57705930-C35D2E90-5DDD-4943-9406-A118815AF03F @default.
- Q57705930 P2860 Q57705930-C77D943F-DD3B-4372-AF75-3E7C6C4149BF @default.
- Q57705930 P2860 Q57705930-E6F4171E-CB7F-4EF6-8416-39D84F72D371 @default.
- Q57705930 P2860 Q57705930-EF8A42FB-80C3-486A-8D01-8EC1FA244505 @default.
- Q57705930 P2860 Q57705930-F0243EA9-F089-41E6-A760-D9DF9F953AE0 @default.
- Q57705930 P2860 Q57705930-F220C61C-675F-4036-B154-D3577C26A629 @default.
- Q57705930 P2860 Q57705930-F42AB121-905C-4F8D-A740-32DC558E7FF9 @default.
- Q57705930 P2860 Q57705930-F8189E10-1F09-4690-AE98-CAAA8BB60C6C @default.
- Q57705930 P304 Q57705930-2A565242-D124-476E-A8C1-457E5206F82D @default.
- Q57705930 P31 Q57705930-4A2FE436-E643-4DF9-AB1D-A655D0BBEC34 @default.
- Q57705930 P356 Q57705930-6563BFD2-8517-4C9E-8D47-B515C11AF1C0 @default.
- Q57705930 P407 Q57705930-4D90D554-BCC2-4E3D-9DD1-F326C273F76A @default.
- Q57705930 P433 Q57705930-420A0348-249C-48DD-B5B3-0AB301E361F7 @default.
- Q57705930 P478 Q57705930-5CF733FC-96F2-4C0A-B4C6-DC7086610314 @default.
- Q57705930 P50 Q57705930-7B83507A-7274-42A3-A45F-B2043E2C16D4 @default.
- Q57705930 P50 Q57705930-93237EAE-7967-453B-BE70-8FFE4AD6247A @default.
- Q57705930 P577 Q57705930-862F0C3D-DCE0-4578-8FD7-5160789A2AE8 @default.
- Q57705930 P698 Q57705930-C62355FD-A948-48BF-A459-2427875DCFCD @default.
- Q57705930 P921 Q57705930-7FD51562-67BB-45CA-A6B1-35602BACCCC6 @default.
- Q57705930 P921 Q57705930-CC4658CB-EBA0-4070-9194-22FCC58CFA06 @default.
- Q57705930 P921 Q57705930-c617f97b-42dd-949d-3a25-8f2b536fa253 @default.
- Q57705930 P921 Q57705930-d7b12393-628e-461c-80b8-960ec6d9236a @default.
- Q57705930 P932 Q57705930-98BC088E-111B-4BFF-9CCF-154226DB6662 @default.
- Q57705930 P356 1346-8138.14504 @default.
- Q57705930 P698 29905383 @default.
- Q57705930 P1433 Q18225322 @default.
- Q57705930 P1476 "Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study" @default.
- Q57705930 P2093 "Hidemi Nakagawa" @default.
- Q57705930 P2093 "Mamitaro Ohtsuki" @default.
- Q57705930 P2093 "Richuan Zheng" @default.
- Q57705930 P2093 "Ryosuke Goto" @default.
- Q57705930 P2860 Q28213628 @default.
- Q57705930 P2860 Q28280453 @default.
- Q57705930 P2860 Q28280465 @default.
- Q57705930 P2860 Q29617131 @default.
- Q57705930 P2860 Q34050062 @default.
- Q57705930 P2860 Q34249937 @default.
- Q57705930 P2860 Q34583765 @default.
- Q57705930 P2860 Q34981499 @default.
- Q57705930 P2860 Q36521222 @default.
- Q57705930 P2860 Q36894005 @default.
- Q57705930 P2860 Q37652760 @default.
- Q57705930 P2860 Q38558536 @default.
- Q57705930 P2860 Q38558538 @default.
- Q57705930 P2860 Q39012808 @default.
- Q57705930 P2860 Q40472720 @default.
- Q57705930 P2860 Q41118310 @default.
- Q57705930 P2860 Q41441414 @default.
- Q57705930 P2860 Q48148751 @default.
- Q57705930 P2860 Q49167189 @default.
- Q57705930 P2860 Q50126864 @default.
- Q57705930 P2860 Q54269757 @default.
- Q57705930 P2860 Q73245623 @default.
- Q57705930 P2860 Q81354813 @default.
- Q57705930 P2860 Q81835985 @default.
- Q57705930 P304 "1053-1062" @default.
- Q57705930 P31 Q13442814 @default.
- Q57705930 P356 "10.1111/1346-8138.14504" @default.
- Q57705930 P407 Q1860 @default.
- Q57705930 P433 "9" @default.
- Q57705930 P478 "45" @default.
- Q57705930 P50 Q42823299 @default.
- Q57705930 P50 Q88143045 @default.
- Q57705930 P577 "2018-06-15T00:00:00Z" @default.